Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01597531 · ClinicalTrials.gov registry record · Phase 4
Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding
A Phase 4 study, sponsored by East Carolina University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT01597531 is a Phase 4 study that was terminated before completion, run by East Carolina University. The registered enrollment target is 1 participants.
The verdict
NCT01597531, a Phase 4 study, was terminated before completion, sponsored by East Carolina University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether addition of 1 or 2 medicines after gastric banding can improve remission of type 2 diabetes.
Interventions
- DRUG Liraglutide
- DRUG Orlistat
- DRUG Liraglutide + Orlistat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01597531
The ClinicalTrials.gov registry entry for NCT01597531 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is East Carolina University, which has 58 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Liraglutide is the first listed.
NCT01597531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01597531 about?
NCT01597531 is a clinical study titled "Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding". The purpose of this study is to determine whether addition of 1 or 2 medicines after gastric banding can improve remission of type 2 diabetes.
What is the current status of trial NCT01597531?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2012-06. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01597531?
The interventions under investigation include: Liraglutide (DRUG), Orlistat (DRUG), Liraglutide + Orlistat (DRUG).
Who is sponsoring clinical trial NCT01597531?
This trial is sponsored by East Carolina University, which has 58 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.